Leyden Labs News and Resources

Leyden Labs, a Dutch biotech company, has secured €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL. The funding will support the clinical development of its pan-influenza nasal spray (PanFlu) and further mucosal platform

Leyden Labs has announced the successful completion of a $70 million funding round aimed at furthering the development of its Mucosal Protection Platform. This non-vaccine approach focuses on the use of broadly protective intranasal antibodies to shield individuals from the